Uptake of HIV Related Care Among Seroconvertors— Implications for VOICE or future HIV prevention trials Sharika Gappoo*, Sarita Naidoo, Yuki Sookrajh,

Slides:



Advertisements
Similar presentations
HIV Counselling and Testing
Advertisements

REASONS FOR LONG-TERM LOSS TO FOLLOW UP OF ADULT ART PATIENTS IN SOUTH AFRICA: A PROSPECTIVE, QUALITATIVE STUDY METHODS RESULTS POLICY RECOMMENDATIONS.
Part A/Module A1/Session 4 Part A: Module A1 Session 4 Comprehensive Care for People Living with HIV/AIDS (PLHA)
Referral of participants for HIV follow-up care Africa Centre MDP experiences Presented by: Hlengiwe Ndlovu MDP Clinic coordinator.
Scaling up Prevention of Mother to Child Transmission of HIV (PMTCT): What Will it Take to Eliminate MTCT? Jessica Rodrigues Presentation for UNICEF Written.
Contraceptive use and uptake Hasinah Asmal, Samantha Govender, Ian Naicker, Dinesh Singh, Gita Ramjee.
RTI International is a trade name of Research Triangle Institute Overview of lessons learned from previous biomedical HIV prevention interventions.
MaxART: Maximizing ART for Better Health and Zero New HIV Infections Strengthening community- and facility-based interventions towards Early Access to.
The role of the Social Worker in ARV Rollout Based on Social Work Practicum Experience at Sinikithemba Clinic, Mc Cord’s Hospital Durban, South Africa.
Community Based Approaches: A review of intervention models and evidence of their effectiveness for preventing maternal-to-child transmission of HIV Joanna.
THE PREVENTION OF MOTHER TO CHILD TRANSMISSION of HIV (PMTCT)
Midwest AIDS Training & Education Center Health Care Education & Training, Inc. HIV/AIDS Case-Finding In Family Planning Clinics.
Positive Living Navajo AIDS Network, Inc. Melvin Harrison, Executive Director Marco Arviso, Arizona Medical Case Manager.
Preliminary findings of a routine PMTCT Option B+ programme in a rural district in Malawi Rebecca M. Coulborn 1, Laura Triviño Duran 1, Carol Metcalf 2,
This presentation and the information contained therein is the sole property of the South African Medical Research Council TREATMENT ACCESS IN TRIALS AND.
Uptake of antiretrovirals in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda J.Bukenya, M. Kwikiriza, O. Musana, J. Ssensamba,
Prevention with Positives; Using Multiple Strategies to Involve Persons Living with HIV in Prevention. TASO Uganda. Emmanuel Odeke,
Involving the Community in HIV/AIDS Treatment Support Programmes: An Evidence-Based Approach.
Project themes in MALAWI: HIV/AIDS Health in prison Climate change.
Community Issues And Needs Associated With Microbicides Clinical Trials Presenter: John M. Mutsambi, Community Liaison Officer with University of Zimbabwe.
Effects of Patient Tracking Systems and Providers Incentives on Patient Appointment Keeping Rwanda Pilot Study Report Nyamusore Jose 1 *, Hinda Ruton 1,
PREVALENCE OF ANAEMIA IN WOMEN AT SCREENING AND FOLLOW-UP IN A MICROBICIDE PHASE III TRIAL Hasinah Asmal, Dinesh Singh, Gita Ramjee HIV Prevention Research.
ACCESS TO TREATMENT BY PEOPLE LIVING WITH HIV IN ZAMBIA Presented by: Kunyima Lifumbela Banda Network of Zambian people living with HIV/AIDS (NZP+)
Community Engagement in clinical trials Projet Ubuzima experience By Marie Michèle UMULISA Community Outreach & Recruitment Manager, Projet Ubuzima.
Microbicide research in Africa: Partnership in Action Salim S. Abdool Karim, MD, PhD Director: CAPRISA Pro Vice-Chancellor (Research): University of KwaZulu-Natal.
Integrating Paediatric HIV/AIDS services into exisitng adult ART services.
Embedding Open-label PrEP trial in expansion of UK HIV Prevention Programme.
Integrated Health Programs for Women and Children: Lessons from the Field Dr. Ambrose Misore Project Director, APHIA II Western, PATH’s Kenya Country Program.
Models of Care for Paediatric HIV Miriam Chipimo MD MPH Reproductive Health & HIV&AIDS Manager, UNICEF, Malawi.
Will Your Partner Be Attending? Involving men in the prevention of mother to child transmission of HIV in antenatal care clinics in Iringa, Tanzania Kikumbih.
PREVENTION OF VERTICAL TRANSMISSION OF HIV: THE FAMILY CENTRED AND COMMUNITY BASED APPROACH IN PERI-URBAN ZAMBIA Presented by Beatrice Chola Executive.
Enabling Continuity of a Public Health ARV Treatment program in a resource limited setting: The Case of the transition of the African Comprehensive HIV/AIDS.
Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.
Background Study Objectives Poster No. B50 Track 2  Family planning affects women’s health and lives, and depends on a variety of socio-demographic and.
Sophia Osawe (BSc, AIMLS) Institute of Human Virology, Nigeria Nigerian Canadian Collaboration on AIDS Vaccines (NICCAV) Study Coordinator Discordant Couples.
DoD/PEPFAR ART Program The Role of Psychosocial Support & Disclosure in pediatric ART – The ‘Mwangalizi’ Project, Kericho 7 th Annual Track 1.0 ART Program.
Bridging the gap between research, MCC approval and public access to tenofovir gel Quarraisha Abdool Karim on behalf of the CAPRISA 008 & CAPRISA 009 teams.
The Methods for Improving Reproductive Health in Africa (MIRA) Study SOC PROGRAM Liz Montgomery Women’s Global Health Imperative RTI International GCM.
Access to Care and Treatment in Microbicide Trials: Findings from the SOC Mapping Exercise Sean Philpott, PhD, MSBioethics Science.
Using Facilitated Referrals to Integrate Family Planning Services into HIV Care and Treatment Clinics in Tanzania Mackenzie S. Green, Mark A. Weaver, Thecla.
1 PREVENTION RESEARCH ADVOCACY COMMUNITY PREPAREDNESS IN HIV PREVENTION TRIALS AND USE OF EXISTING METHODOLOGIES MDP 301 trial in Mwanza, Tanzania Charles.
Promoting Rational Use of ARVs in HIV/AIDS Clinics in Tanzania Presented by Salama Mwakisu -MSH.
Module 2: Learning Objectives
HOW ARE MDP PREPARING COMMUNITIES AT TRIAL SITES? MDP301.
Providing Treatment, Restoring Hope Secondary Prevention as part of HIV Clinical Care Martine Etienne, MPH, DrPH University of Maryland School of Medicine.
Ensuring Adherence and Retention to HIV Care and Treatment among Orphans and Vulnerable Children A Multi-Country Experience Thebisa Chaava MPH Senior Technical.
Prevention trials pipeline MOSY3. Willard Cates, HIV Prevention Research: The Optimist’s.
Improving Appointment Keeping and Adherence Monitoring In ART Facilities in Kenya: Views of Providers and Patients Susan Njogo National AIDS/STI Control.
Dr Rochelle Adams ACC Project Manager On behalf of the ACC team AWACC November 2015 Health systems Strengthening for Success and Sustainability.
AN INTERNATIONAL MULTI-CENTRE, RANDOMISED, DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF 0.5% AND 2% PRO 2000 GELS FOR.
Care for seroconverters in CONRAD’s Cellulose Sulfate HIV Prevention Trial Lut Van Damme Global Campaign meeting June 2008.
COMMUNITY HIV TESTING taking the clinic to the community Presented by: Priscilla Matyanga OPHID Trust Community Facilitator 2015 PSS Conference Victoria.
Providing Care and Treatment for HIV Sero-convertors in the Cellulose Sulfate Trial Issues for discussion Preparation process for care and treatment of.
HPTN Ethics Guidance for Research: Community Obligations Africa Regional Working Group Meeting, May 19-23, 2003 Lusaka, Zambia.
International Partnership for Microbicides Approach to HIV Treatment and Care in Future IPM Microbicide Trials Pam Norick, Chief of External Relations.
WAD SYMPOSIUM 2014 ART Adherence and Retention: MDH Experience Eric Aris Management and Development for Health 29 th November 2014 NJOMBE.
United Republic of Tanzania Ministry of Health & Social Welfare MINISTRY OF HEALTH AND SOCIAL WELFARE NATIONAL AIDS CONTROL PROGRAM HIV CARE AND TREATMENT.
Factors contributing to diaphragm size change in a Clinical Trial HIV PREVENTION RESEARCH UNIT Govender SM; Mtungwa LN; Manarsingh F; Naidoo VH; Ramjee.
BARRIERS TO AND FACILITATORS FOR RETENTION OF MOTHER BABY-PAIRS IN CARE IN ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV IN EASTERN UGANDA Gerald.
Provider Initiated HIV Counseling and Testing Unit 2: Introduction and Rational for PIHCT.
1 Module 2: HIV Counseling and Testing for PMTCT Ministry of Health/HAPCO, Ethiopia.
From Aggregate Indicators to Impacting Patients - Data Use to Inform Treatment and Improve Care Ian Wanyeki Track 1.0 Implementers Meeting Dar Es Salaam.
Integrated services for people who use drugs in vertical health care systems: challenges and solutions Kostyantyn Dumchev, MD, MPH July 19, st.
HPTN 071 (PopART): Have we reached the targets after two years of the PopART intervention IAS Paris July 2017 Richard Hayes.
How differentiated care supports “Tx all” and Dr
HIV+ children and young people have complex family and health contexts: results from a case note review in a London treatment centre. Tomás Campbell, Hannah.
Getting to the second 90 in adolescent HIV: What is needed
Cross-sectional assessment of patient outcomes using a systematic file review process: Results from 12,987 patient files Ambereen Jaffer, Gesine Meyer-Rath,
A COLLABORATIVE APPROACH TO ESTABLISH PREDICTORS
Participant Retention
Presentation transcript:

Uptake of HIV Related Care Among Seroconvertors— Implications for VOICE or future HIV prevention trials Sharika Gappoo*, Sarita Naidoo, Yuki Sookrajh, Neetha Morar and Gita Ramjee HIV Prevention Research Unit, Medical Research Council, South Africa The MDP 301 trial was implemented at 3 trial sites in Durban (Tongaat, Verulam and Isipingo) and enrolled 2391 women. All seroconvertors received a referral for further HIV related management to:  PEPFAR Care Clinic (operating at the Verulam HPRU clinic)  SPARTAC Treatment Trial  Local DoH service provider Seroconvertors were contacted telephonically or via home visits to assess the uptake of these referrals and any challenges encountered. The SPARTAC trial is a randomised, controlled clinical trial that is currently conducted at 6 sites in Durban (Verulam, Isipingo, Umkomaas, Chatsworth, Botha’s Hill and Overport). Participants who were acutely infected with HIV (HIV positive antibody test within 6- months of an HIV negative antibody test ) were randomised to 1 of 3 arms i.e. 48 weeks ARV treatment, 12 weeks ARV treatment or No therapy and followed for a period of 3.5 – 5 years. CD4 and Viral Loads were monitored during this period. Between 2005 and 2007, 155 newly infected HIV positive women were recruited from then ongoing HPRU HIV prevention clinical trials. Of these, 87 enrolled into the SPARTAC trial. Each participant was referred to the closest DoH clinic from the onset of the trial for further care, monitoring and enrolment into the National ARV programme. To ensure that women did enrol into some care programme, staff tried to facilitate the process by providing transport, booking appointments and accompanying participants for visits. Assessment on the uptake of referrals was done at each visit for participants during the year period. Participant were requested to produce documents such as their clinic cards or feedback on their referral letters confirming enrolment into the national ARV programme. Acknowledgements: The participants of MDP and Spartac trials, The HPRU staff that contributed to the data, The Microbicides Development Programme (MDP) is a partnership of African, UK and Spanish academic/government institutions and commercial organisations., MDP is funded by the British Government Department for International Development (DIFD) and the UK Medical Research Council. MDP trial ISRCTN number is: ISRCTN , The Clinical Trials Unit: SPARTAC Team; Welcome Trust: Subcontract Agreement Protocol No.:09 The HIV Prevention Research Unit (HPRU) of the Medical Research Council conducts research focusing mainly on female controlled HIV prevention options. Over the past 7 years the HPRU as conducted 5 large phase III clinical trials assessing different interventions for HIV prevention and enrolled over 7000 women. The trials were conducted at 7 community based research sites in the Durban and surrounding areas. Given the high HIV prevalence and incidence in our setting, every effort was made to integrate HIV prevention with treatment and care. BACKGROUND INTRODUCTION Access to HIV related care in resource poor settings can be attributed to the unavailability of efficient health services, financial constraints, stigma and other social barriers to care. Although South Africa has an established ARV Treatment programme, at the end of 2007 less than 31% of adults and children requiring ARV therapy were receiving it. To help facilitate the referral process of trial participants to accessing care, the HPRU established a Memorandum of Understanding (MOU) with the Provincial Department of Health (DoH) and its associated service providers. This MOU was intended to help trial participants to access care related to HIV/AIDS, reproductive health and psychosocial care. The Referral process included: Counselling HIV positive participants at sites and then referring them for ongoing care to a public health service provider. Provision of a referral letter by the attending clinician or counsellor. Maintaining and updating a Referral log to include the details of the service providers closest to the trial sites. This sub-study examines the outcomes of the referrals provided to participants for HIV related care for 2 trials- -- HIV prevention trial: MDP 301- A randomised controlled trial testing Pro 2000 (05% and 2%) microbicide gel in 4 countries in Africa HIV treatment trial: SPARTAC- (Short Pulse Antiretroviral Therapy at HIV Seroconversion). METHODS CONCLUSION RESULTS OBJECTIVES  To assess the access of HIV related care referrals by participants in the SPARTAC and MDP 301 Clinical Trials  To Identify common reasons for not accessing referrals for care at local DoH service providers  Despite having adequate referral systems and formalised partnerships with Health Care facilities, ensuring uptake of HIV related referral by participants who were HIV positive was a challenge.  Given the high HIV incidence in our setting, monitoring and evaluation of HIV related care by research participants is of utmost importance. Having and MOU may not suffice as there are multiple reasons for not accessing care.  The reasons identified as barriers to accessing care requires community wide intervention coupled with targeted counselling on a case by case basis.  For new trials such as VOICE (Vaginal and Oral Intervention to Control the Epidemic) HIV seroconvertors who may be exposed to ARV based intervention will require a more stringent mechanism to assess access to care which will include monitoring and evaluation of various factors that impede on participants accessing HIV related care. Reasons for not accessing care (MDP 301 and SPARTAC)  Fear of disclosure of HIV status to family and/or friends  Stigma and discrimination: Many women knew people working at the clinics and were afraid of them discovering their HIV status.  Denial of their HIV status despite being positive for 3-4 years  Concerns on the side effects of ARVs: By participants and their families  Work commitments: Some women were too busy and could not afford missing work  Cost implications: High cost of travelling to and from the clinics  Distance: Some women reported that clinics are not easily accessible  Use of traditional medicines: Some women opted for traditional medicines while others were forced or influenced by their families.  Current Health Status: Many women report still feel healthy soon after seroconverting and don’t understand the implications of not enrolling into a programme. Total participants enrolled N= 2391 No. seroconverted 165 Maintained contact 104 (63%) Lost contact /LTFU 61(37%) Accessed Referrals 77 (74%) Enrolled in treatment Trial 11 (11%) Refused to access care 16 (15%) Access to care by seroconvertors: MDP 301 Trial Access to care by participants: SPARTAC Trial HIV prevention Trial No. enrolled in SPARTAC MIRA Trial: Testing the diaphragm as Cervical Barrier to HIV31 Pop Council: Testing Carraguard microbicide gel35 CONRAD: Testing Cellulose Sulphate microbicide gel7 HPTN 035: Testing Pro 2000 (0.5%) and Buffer Gel3 MDP 301: Testing Pro 2000 (0.5% and 2%)11 For most women it took several counselling sessions and a lot of encouragement before they eventually attended local clinics Many did not take up referrals due mainly to denial, stigma and other commitments (work, caring for children, etc.) These 11 women joined the SPARTAC trial and are currently receiving care through this project Total enrolled in SPARTAC Trial N = 87 Enrolled into National Programme 67 (77%) Not Enrolled in National Programme 15 (17%) Deceased/LFTU 5 (6%) Of the 12 eligible for ARVs (CD4<200 copies/ul)- 11 are currently on long term treatment Previously enrolled in National ARV Programme but discontinued 10 (67%) Never attended Referral centre 5 (33%) Reasons for not attending follow up include: Time and cost constraints. Some do not have treatment supporter that can attend treatment classes with them Some participants are still in denial of their HIV status or still feel healthy and don’t see the urgency to attend. MDP 301 Trial Referral Process SPARTAC Trial Referral Process 472